Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

Brain : a journal of neurology - 1 Jun 2003

Stürzebecher S, Wandinger K P, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, Frank J A, Staudt L, Martin R, McFarland H F

Abstract excerpt

Autoimmune diseases such as multiple sclerosis are characterized by complex genetic traits and pathomechanisms that translate into clinical heterogeneity. This wide heterogeneity of multiple sclerosis as well as different biological responses to immunomodulatory drugs can be expected to contribute to differential treatment responses. Strategies that dissect the relationship between the treatment response and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Follow-Up Studies
Share to Interferon-beta

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Magnetic Resonance Imaging

Share to Multiple Sclerosis

Share to Oligonucleotide Array Sequence Analysis

Share to Recombinant Proteins

Share to Recurrence

Share to Treatment Failure

Source

Identifiers

PMID: 12764062
DOI: 10.1093/brain/awg147

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.PMID 12764062Read ↗

Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.Semantic proximity Read ↗

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between PatientsSemantic proximity Read ↗

An RNA Profile Identifies Two Subsets of Multiple Sclerosis Patients Differing in Disease ActivitySemantic proximity Read ↗

IFN-beta pharmacogenomics in multiple sclerosis.Semantic proximity Read ↗

Genomic effects of IFN-beta in multiple sclerosis patients.Semantic proximity Read ↗

Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.Semantic proximity Read ↗

Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients’ individual gene expression in peripheral bloodSemantic proximity Read ↗

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.Semantic proximity Read ↗

Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment.Semantic proximity Read ↗

Long-Term Genome-Wide Blood RNA Expression Profiles Yield Novel Molecular Response Candidates for IFN-β-1b Treatment in Relapsing Remitting MSSemantic proximity Read ↗

Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genesSemantic proximity Read ↗

Blood transcriptional signatures of multiple sclerosis: Unique gene expression of disease activitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.